MOUNTAIN VIEW, Calif.,
March 21, 2016 /PRNewswire/
-- Omnicell, Inc., (NASDAQ: OMCL), today announced it is
realigning its organization to continue its growth strategy of
offering differentiated products, expanding into new markets and
increasing its presence through acquisitions. Over the past year,
Omnicell has expanded its solutions and market reach through a
series of acquisitions and new product announcements. The new
organization will assure focus at the highest levels of the company
on the successful integration of the acquisitions while
simultaneously sustaining the momentum of new product innovation
and expansion into new markets.
In the new organizational structure, Christopher Drew has been named President, North
American Automation and Analytics, and Rob
Seim has been named President, Global Automation and
Medication Adherence. Randall A. Lipps, founder of Omnicell,
continues to lead the overall business strategy of the Company in
his role as Omnicell Chairman, President, and Chief Executive
Officer.
The acquisition of Aesynt in January
2016 expanded the Omnicell portfolio of medication and
medical supply automation products, and added approximately 1,000
new customers to Omnicell's installed base. As President, North
American Automation and Analytics, Mr. Drew is responsible for
North American Sales, Marketing, Operations and Service for the
automation and analytics product lines, where most of the Aesynt
integration activity is taking place. This new organization is
aligned to assure that the integration of Aesynt into Omnicell
continues to provide customers the best possible value from the
unprecedented choice of solutions now offered. This choice is
expected to grow even further as the power of the combined product
development organizations delivers a stream of differentiated new
solutions to the market. Mr. Drew's 22-year Omnicell career
includes senior leadership roles in Sales, Service, Operations,
Corporate Development, Engineering and Manufacturing. Prior to
joining Omnicell, he worked for The Goldman Sachs Group, Inc.
The broad range of Omnicell solutions includes medication
adherence, IV automation, and specialized automation for
international pharmacies, all of which have accelerated the growth
of Omnicell in new markets. Many of these solutions and new markets
represent substantial long-term growth opportunities for Omnicell.
As President, Global Automation and Medication Adherence, Mr. Seim
is responsible for the Company's long-term growth strategies in new
product and market areas, which include medication adherence, IV
compounding, and robotic dispensing system products, as well as
non-acute markets and markets outside North America. Mr. Seim
will also continue to functionally manage Global Manufacturing and
Global Quality. During his 10 years with Omnicell, Mr. Seim served
as Chief Financial Officer and Executive Vice President of Finance,
Administration and Manufacturing. Prior to joining Omnicell, Mr.
Seim held senior finance and leadership roles at both early stage
and fast-growing companies. Mr. Seim began his career at IBM where
he served over 14 years in a variety of financial positions over
the course of his tenure.
"We are well-positioned for success in the health care industry
with this new organization, and we are fortunate to have incredible
depth and breadth of talent across Omnicell's executive team," said
Randall A. Lipps, Omnicell founder,
chairman, president and CEO. "Chris and Rob have both made
significant contributions to the success of Omnicell, and their
expanded roles provide strategic and operational focus that will
further our industry leadership."
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including but not limited to statements relating to the anticipated
benefits of the acquisition of Aesynt and the expected
combined operations
of Omnicell and Aesynt going forward. As such,
they are subject to the occurrence of many events
outside Omnicell's control and are subject to various
risk factors that could cause actual results to differ materially
from those expressed or implied in any forward-looking statement.
Risks include, without limitation, risks associated with the
acquisition of Aesynt, such as the risk that the businesses
will not be integrated successfully, that such integration may be
more difficult, time-consuming or costly than expected or that the
expected benefits of the acquisition will not occur; risks related
to future opportunities and plans for the combined company,
including uncertainty of the expected financial performance and
results of the combined company following completion of the
acquisition, including anticipated non-GAAP accretive results and
revenue; disruption from the integration process, making it more
difficult to conduct business as usual or maintain relationships
with customers, employees or suppliers; the calculation of, and
factors that may impact the allocation of the purchase price to the
net assets acquired in accordance with applicable accounting rules
and methodologies; the possibility that if Omnicell does
not achieve the perceived benefits of the acquisition
of Aesynt as rapidly or to the extent anticipated by
financial analysts or investors, the market price
of Omnicell's shares could decline; and risks related to
the incurrence of debt, including potential impairment of our
flexibility and access to capital, and increased interest
obligations. Other risks that contribute to the uncertain nature of
the forward-looking statements include our ability to take
advantage of the growth opportunities in international markets or
in medication management markets across the spectrum of health care
settings, unfavorable general economic and market conditions, risks
to growth and acceptance of our products and services, and to
growth of the clinical automation and workflow automation market
generally, the potential of increasing competition, potential
regulatory changes, the ability of the company to improve sales
productivity to grow product bookings, to develop new products and
to acquire and successfully integrate companies. These and other
risks and uncertainties are described more fully in Omnicell's
most recent filings with the Securities and Exchange
Commission. Prospective investors are cautioned not to place undue
reliance on forward-looking statements. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Omnicell undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been creating innovative
solutions to improve patient care, anywhere it is delivered.
Omnicell is a leading supplier of comprehensive automation and
business analytics software for medication and supply management
across the entire health care continuum—from the acute care
hospital setting, to post-acute skilled nursing and long-term care
facilities, to the patient's home.
Approximately 4,000 customers worldwide use Omnicell automation
and analytics solutions to increase operational efficiency, reduce
medication errors, deliver actionable intelligence and improve
patient safety. The recent acquisition of Aesynt adds distinct
capabilities, particularly in central pharmacy and IV robotics,
creating the broadest medication management product portfolio in
the industry.
The Omnicell SureMed solution provides innovative medication
adherence packaging to help reduce costly hospital readmissions. In
addition, these solutions enable approximately 7,000 institutional
and retail pharmacies worldwide to maintain high accuracy and
quality standards in medication dispensing and administration while
optimizing productivity and controlling costs.
For more information about Omnicell, Inc. please visit
http://www.omnicell.com/.
OMCL-G
Editor's Notes:
- All Omnicell news releases (financial, acquisitions, products,
technology etc.) are issued exclusively by PR Newswire and are
immediately thereafter posted on the company's external website,
omnicell.com.
- Omnicell and the Omnicell logo design are registered trademarks
of Omnicell, Inc.
- All other brand or product names may be trademarks or
registered trademarks of their respective companies.
Logo -
http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/omnicell-announces-organizational-realignment-to-increase-strategic-and-operational-focus-300239014.html
SOURCE Omnicell, Inc.